Bioinformatics Market Will Reach $11.43bn In 2020, According To New Visiongain Analysis

31 August 2018
Pharma

Visiongain’s study predicts expansion in the bioinformatics market will continue until 2026, especially in the genomics sector, which will remain dominant. The chemoinformatics and drug discovery sector will have the highest revenue growth rate during this period, as the use of bioinformatics in personalised medicine increases. In 2015, the genomics submarket formed the most lucrative part of that industry, accounting for 48.6% of the overall world market. As the bioinformatics market grows, this segment will continue to dominate.

The report’s author said: “The bioinformatics market has strong potential, with many innovative software platforms that can offer analysis of not only genomic data but proteomic, transcriptomic and chemoinformatic data. With so many sources of data, a company that can offer integrated analysis and interpretation will have a competitive edge. Researchers will also be looking to bioinformatics companies to provide security and flexibility such as cloud-based bioinformatics to facilitate collaborations and enable data access from anywhere. An important restraint on growth of the market will be a shortage of trained expertise; over our forecast period the success of the market will depend on remedying this deficit. The bioinformatics market will continue to expand, bolstered by governmental investment and lower costs of sequencing, as the trend towards personalised medicine ensures that demand stays strong.”

Visiongain’s new investigation shows bioinformatic revenue predictions to 2026 at overall world market, submarket and regional level. First it forecasts the following segments of the bioinformatics market to 2026:

• Genomics
• Metabolomics
• Proteomics
• Transcriptomics
• Chemoinformatics and drug discovery
• Other applications.

That work also analyses leading national markets for those informatics tools, providing revenue forecasts to 2026 for these countries and regions:

• United States
• European Union
• Japan
• China
• India
• Rest of the world.

In addition visiongain’s survey examines leading bioinformatic companies. That study discusses mergers and acquisitions, collaborations and developments, also showing a research interview. The report highlights organisations such as these:

• QIAGEN
• Illumina
• Thermo Fisher Scientific
• 3rd Millennium
• DNASTAR
• DNAnexus
• Compugen.

Bioinformatics Market Analysis, Developments and Forecasts 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services, including contract research, manufacturing and selling. Each year new and updated studies appear.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever